A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes
The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Background: There is growing interest in glutamatergic agents in depression, particularly ketamine, a glutamate N -methyl- d -aspartate (NMDA) receptor antagonist. We aimed to assess the efficacy of ketamine in major depressive episodes. Method: We searched EMBASE, PsycINFO, CENTRAL, and Medline from 1962 to January 2014 to identify double-blind, randomized controlled trials with allocation concealment evaluating ketamine in major depressive episodes. Clinical remission, response and depressive symptoms were extracted by two independent raters. The primary outcome measure was clinical remission at 24 h, 3 days and 7 days post-treatment. Analyses employed a random-effects model. Results: Data were synthesized from seven RCTs employing an intravenous infusion and one RCT employing intranasal ketamine, representing 73 subjects in parallel arms and 110 subjects in cross-over designs [ n = 34 with bipolar disorder (BD), n = 149 with major depressive disorder (MDD)]. Ketamine was associated with higher rates of clinical remission relative to comparator (saline or midazolam) at 24 h [OR 7.06, number needed to treat (NNT) = 5], 3 days (OR 3.86, NNT = 6), and 7 days (OR 4.00, NNT = 6), as well as higher rates of clinical response at 24 h (OR 9.10, NNT = 3), 3 days (OR 6.77, NNT = 3), and 7 days (OR 4.87, NNT = 4). A standardized mean difference of 0.90 in favor of ketamine was observed at 24 h based on depression rating scale scores, with group comparisons revealing greater efficacy in unipolar depression compared to bipolar depression (1.07 v. 0.68). Ketamine was associated with transient psychotomimetic effects, but no persistent psychosis or affective switches. Conclusion: Our meta-analysis suggests that single administrations ketamine are efficacious in the rapid treatment of unipolar and bipolar depression. Additional research is required to determine optimal dosing schedules, route, treatment schedules, and the potential efficacy of other glutamatergic agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Not only do they produce sustained therapeutic effects following a single administration, they also appear to have broad therapeutic potential”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [39]
In the citing paper
“Unlike traditional antidepressants, psychoplastogens produce both fast-acting and sustained beneficial behavioral effects after a single administration (Figure 1) (38–42).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [39]
In the citing paper
“Multiple meta-analyses55–59 have now concluded that intravenous ketamine is effective as a rapid-acting antidepressant for major depressive episodes in both unipolar and bipolar depression”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [57]
In the citing paper
“although one study suggested that there was a greater antidepressant effect size for unipolar depression than for bipolar.57”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [57]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 2×
“Finally, we used funnel plots, Rosenthal’s fail-safe N (Rosenthal, 1979), and Egger’s regression intercept (Egger et al. 1997) to test for the presence of publication bias (Borenstein et al.”
MethodThe Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“Primary outcome measure: Clinical remission, defined as a Hamilton Depression Rating Scale (HAMD; Hamilton, 1960) score of <7 or a Montgomery– Asberg Depression Rating Scale (MADRS; Montgomery & Asberg, 1979) score of <10.”
MethodCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 1×
“Studies were included if they satisfied all of the following criteria (Higgins & Green, 2008): • Study validity: Random allocation; allocation concealment; double-blind; placebo-controlled; parallel or cross-over design; 55 subjects per study arm; clinician-rated primary outcome measure.”
MethodBorenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · doi:10.1002/9780470743386 · Cited by 14,225
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“Primary outcome measure: Clinical remission, defined as a Hamilton Depression Rating Scale (HAMD; Hamilton, 1960) score of <7 or a Montgomery– Asberg Depression Rating Scale (MADRS; Montgomery & Asberg, 1979) score of <10.”
MethodThe Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 1×
“Psychotomimetic and dissociative symptoms as measured by the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962) and the Clinician Administered Dissociative States Scale (CADSS; Bremner et al. 1998).”
MethodBorenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021) · doi:10.1002/9781119558378 · Cited by 9,799
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
The file drawer problem and tolerance for null results.
Rosenthal, R. (1979) · Psychological Bulletin · doi:10.1037/0033-2909.86.3.638 · Cited by 9,068 · cited 2×
“Finally, we used funnel plots, Rosenthal’s fail-safe N (Rosenthal, 1979), and Egger’s regression intercept (Egger et al. 1997) to test for the presence of publication bias (Borenstein et al. 2009; Cooper et al. 2009).”
MethodRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
The Handbook of Research Synthesis and Meta-Analysis
(2019) · doi:10.7758/9781610448864 · Cited by 4,553 · cited 4×
“Heterogeneity was assessed using Q statistics and I(2) (Cooper et al. 2009) and two-tailed p values reported.”
BackgroundMethodInfluentialMeta-Analytic Procedures for Social Research.
Metcalfe, A., & Rosenthal, R. (1994) · The Statistician · doi:10.2307/2348600 · Cited by 4,249
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 25×
“double-blind cross-over RCTs (Berman et al. 2000; Zarate et al. 2006, 2012; Diazgranados et al. 2010; Sos et al. 2013; Lapidus et al. 2014) (n=110), while one was a parallel arm RCT (Murrough et al.”
BackgroundMethodResultInfluentialA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 20×
“M cG irr et al. double-blind cross-over RCTs (Berman et al. 2000; Zarate et al. 2006, 2012; Diazgranados et al. 2010; Sos et al. 2013; Lapidus et al. 2014) (n=110), while one was a parallel arm RCT (Murrough et al. 2013a) (n=73).”
BackgroundMethodInfluentialInterpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884 · cited 1×
“Given that true treatment effects likely vary between studies given methodological differences, we used a random-effects model (Riley et al. 2011).”
MethodMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 14×
“M cG irr et al. double-blind cross-over RCTs (Berman et al. 2000; Zarate et al. 2006, 2012; Diazgranados et al. 2010; Sos et al. 2013; Lapidus et al. 2014) (n=110), while one was a parallel arm RCT (Murrough et al. 2013a) (n=73).”
BackgroundMethodInfluentialDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 15×
“M cG irr et al. double-blind cross-over RCTs (Berman et al. 2000; Zarate et al. 2006, 2012; Diazgranados et al. 2010; Sos et al. 2013; Lapidus et al. 2014) (n=110), while one was a parallel arm RCT (Murrough et al. 2013a) (n=73).”
BackgroundMethodInfluentialTargeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894 · cited 1×
“The search for novel targets has stimulated interest in the glutamatergic system (Skolnick et al. 1996; Sanacora et al. 2008; Skolnick et al. 2009).”
BackgroundBremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 1×
“Psychotomimetic and dissociative symptoms as measured by the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962) and the Clinician Administered Dissociative States Scale (CADSS; Bremner et al. 1998).”
MethodZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 20×
“M cG irr et al. double-blind cross-over RCTs (Berman et al. 2000; Zarate et al. 2006, 2012; Diazgranados et al. 2010; Sos et al. 2013; Lapidus et al. 2014) (n=110), while one was a parallel arm RCT (Murrough et al. 2013a) (n=73).”
BackgroundMethodInfluentialMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 14×
“M cG irr et al. double-blind cross-over RCTs (Berman et al. 2000; Zarate et al. 2006, 2012; Diazgranados et al. 2010; Sos et al. 2013; Lapidus et al. 2014) (n=110), while one was a parallel arm RCT (Murrough et al. 2013a) (n=73).”
BackgroundMethodInfluentialFunctional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · cited 1×
“Moreover, animal data suggests that antagonism of N-methyl-D-aspartate (NMDA) receptors, an ionotropic subpopulation of glutamate receptors, is associated with antidepressant effects (Trullas & Skolnick, 1990; Przegalinski et al. 1997).”
BackgroundPost-randomisation exclusions: the intention to treat principle and excluding patients from analysis
Fergusson, D., Aaron, S. D., Guyatt, G., & Hébert, P. (2002) · BMJ · doi:10.1136/bmj.325.7365.652 · Cited by 708 · cited 1×
“Analyses were restricted to intention-to-treat data (Fergusson et al. 2002).”
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690 · cited 1×
“…efforts, while still involving open label designs, suggest that higher and sustained rates of response and remission can be achieved with repeated doses (aan het Rot et al. 2010; Murrough et al. 2013b; Rasmussen et al. 2013; Shiroma et al. 2014); however, comparison to single dose is still lacking.”
BackgroundDeeks, J. J. (2002) · Statistics in Medicine · doi:10.1002/sim.1188 · Cited by 660 · cited 1×
“The efficacy of ketamine was investigated by odds ratios (ORs) (Deeks, 2002), number needed to treat (NNT), and standardized mean differences (SMD).”
BackgroundConradi, H. J., Ormel, J., & de Jonge, P. (2011) · Psychological Medicine · doi:10.1017/s0033291710001911 · Cited by 515 · cited 1×
“These disorders are usually chronic, characterized by relapsing remitting courses and significant impairment persisting even during periods of remission (Fagiolini et al. 2005; Conradi et al. 2011).”
BackgroundA Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480 · cited 23×
“double-blind cross-over RCTs (Berman et al. 2000; Zarate et al. 2006, 2012; Diazgranados et al. 2010; Sos et al. 2013; Lapidus et al. 2014) (n=110), while one was a parallel arm RCT (Murrough et al.”
BackgroundMethodInfluentialGeddes, J. R., Calabrese, J. R., & Goodwin, G. M. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048504 · Cited by 434 · cited 1×
“Indeed, there is evidence for the efficacy of agents that directly target glutamatergic system such as lamotrigine (Geddes et al. 2009) in bipolar * Address for correspondence: A. McGirr, 11th Floor, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada (Email:…”
BackgroundKetamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418 · cited 1×
“Since the initial report by Berman et al. (2000) that ketamine produces a rapid and marked antidepressant effect, there have been several efforts to replicate and extend this finding (aan het Rot et al. 2012).”
ResultSequeira, A., Mamdani, F., Ernst, C., Vawter, M. P., Bunney, W. E., Lebel, V., Rehal, S., Klempan, T., Gratton, A., Benkelfat, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006585 · Cited by 388 · cited 1×
“Post-mortem characterizations support the notion of dysfunctional glutamatergic signaling in MDD and BD (Knable et al. 2002; Sequeira et al. 2009; Deschwanden et al. 2011).”
BackgroundGlutamate-based antidepressants: 20 years on
Skolnick, P., Popik, P., & Trullas, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 380
Skolnick, P., Layer, R., Popik, P., Nowak, G., Paul, I., & Trullas, R. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979537 · Cited by 344 · cited 1×
“The search for novel targets has stimulated interest in the glutamatergic system (Skolnick et al. 1996; Sanacora et al. 2008; Skolnick et al. 2009).”
BackgroundAn Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression
Zarate, C. A., Payne, J. L., Quiroz, J., Sporn, J., Denicoff, K. K., Luckenbaugh, D., Charney, D. S., & Manji, H. K. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.171 · Cited by 324 · cited 1×
“© Cambridge University Press 2014 doi:10.1017/S0033291714001603 REVIEW ARTICLE depression and riluzole in major depression (Zarate et al. 2004).”
BackgroundInfluentialDo the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283 · cited 1×
“An additional concern that has been the psychotomimetic side effects experienced during ketamine infusions and the ensuing safety concerns; however, there is some evidence to suggest that such side-effects may be related to ketamine’s antidepressant effectiveness (Luckenbaugh et al. 2014).”
BackgroundDeschwanden, A., Karolewicz, B., Feyissa, A. M., Treyer, V., Ametamey, S. M., Johayem, A., Burger, C., Auberson, Y. P., Sovago, J., Stockmeier, C. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.09111607 · Cited by 278 · cited 1×
“Post-mortem characterizations support the notion of dysfunctional glutamatergic signaling in MDD and BD (Knable et al. 2002; Sequeira et al. 2009; Deschwanden et al. 2011).”
BackgroundZarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255 · cited 1×
“A growing area of research is the exploration of NMDA antagonists without the psychotomimetic effects of ketamine, and there are already positive trials with such agents [AZD6765 (Sanacora et al. 2013; Zarate et al. 2013)], albeit with a lower level of efficacy.”
BackgroundHaile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253 · cited 1×
“In clinically depressed samples, peripheral brain-derived neurotrophic factor increases with NMDA antagonism (Haile et al. 2014).”
BackgroundKetamine for Treatment-Resistant Unipolar Depression: Current Evidence
Mathew, S. J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., & Murrough, J. W. (2012) · CNS Drugs · doi:10.2165/11599770-000000000-00000 · Cited by 238 · cited 1×
“Oral ketamine, however, has limited bioavailability, and therefore other methods of administration are being investigated, including intramuscular and intranasal routes (Mathew et al. 2012; Lapidus et al. 2014).”
BackgroundSanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236 · cited 1×
“A growing area of research is the exploration of NMDA antagonists without the psychotomimetic effects of ketamine, and there are already positive trials with such agents [AZD6765 (Sanacora et al. 2013; Zarate et al. 2013)], albeit with a lower level of efficacy.”
BackgroundShiroma, P. R., Johns, B., Kuskowski, M., Wels, J., Thuras, P., Albott, C. S., & Lim, K. O. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.036 · Cited by 221 · cited 2×
“…efforts, while still involving open label designs, suggest that higher and sustained rates of response and remission can be achieved with repeated doses (aan het Rot et al. 2010; Murrough et al. 2013b; Rasmussen et al. 2013; Shiroma et al. 2014); however, comparison to single dose is still lacking.”
BackgroundSerial infusions of low-dose ketamine for major depression
Rasmussen, K. G., Lineberry, T. W., Galardy, C. W., Kung, S., Lapid, M. I., Palmer, B. A., Ritter, M. J., Schak, K. M., Sola, C. L., Hanson, A. J., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478283 · Cited by 217 · cited 2×
“…efforts, while still involving open label designs, suggest that higher and sustained rates of response and remission can be achieved with repeated doses (aan het Rot et al. 2010; Murrough et al. 2013b; Rasmussen et al. 2013; Shiroma et al. 2014); however, comparison to single dose is still lacking.”
BackgroundFunctional impairment in the remission phase of bipolar disorder
Fagiolini, A., Kupfer, D. J., Masalehdan, A., Scott, J. A., Houck, P. R., & Frank, E. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00207.x · Cited by 206
(2013) · PubMed · Cited by 192
Small-Dose Ketamine Improves the Postoperative State of Depressed Patients
Kudoh, A., Takahira, Y., Katagai, H., & Takazawa, T. (2002) · Anesthesia & Analgesia · doi:10.1097/00000539-200207000-00020 · Cited by 189 · cited 2×
“The first of these involved randomizing MDD patients (n=70) to ketamine or propofol in a surgical setting (Kudoh et al. 2002), and the second involved randomizing MDD patients (n=18) to repeated ketamine infusions or a similar number of electroconvulsive therapy treatments (Ghasemi et al. 2013).”
BackgroundA randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177 · cited 2×
“2013) and D-cycloserine administered chronically in treatment-resistant depression (Heresco-Levy et al. 2013).”
BackgroundResultKetamine as a Novel Antidepressant: From Synapse to Behavior
Murrough, J. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.244 · Cited by 172 · cited 1×
“Ketamine’s mechanism of action in depression remains elusive (Murrough, 2012).”
BackgroundIrwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167 · cited 3×
“There is currently open-label evidence to suggest benefit of oral ketamine (Irwin et al. 2013; Lara et al. 2013), including sublingual administration (Lara et al. 2013); however, efficacy data is lacking.”
BackgroundGhasemi, M., Kazemi, M., Yoosefi, A., Ghasemi, A., Paragomi, P., Amini, H., & Afzali, M. H. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.008 · Cited by 162 · cited 2×
“The first of these involved randomizing MDD patients (n=70) to ketamine or propofol in a surgical setting (Kudoh et al. 2002), and the second involved randomizing MDD patients (n=18) to repeated ketamine infusions or a similar number of electroconvulsive therapy treatments (Ghasemi et al. 2013).”
BackgroundInhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression
Huang, C., Wei, I., Huang, C.-L., Chen, K.-T., Tsai, M., Tsai, P., Tun, R., Huang, K.-H., Chang, Y., Lane, H., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.020 · Cited by 152 · cited 2×
“support the antidepressant effects of NMDA agonists, for example a recent report of oral sarcosine in depressed patients (Huang et al. 2013) and D-cycloserine administered chronically in treatment-resistant depression (Heresco-Levy et al.”
BackgroundResultLara, D. R., Bisol, L. W., & Munari, L. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000485 · Cited by 138 · cited 1×
“There is currently open-label evidence to suggest benefit of oral ketamine (Irwin et al. 2013; Lara et al. 2013), including sublingual administration (Lara et al. 2013); however, efficacy data is lacking.”
BackgroundPrzegaliński, E., Tatarczynska, E., Dereń-Wesołek, A., & Chojnacka-Wójcik, E. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00157-8 · Cited by 117 · cited 1×
“Moreover, animal data suggests that antagonism of N-methyl-D-aspartate (NMDA) receptors, an ionotropic subpopulation of glutamate receptors, is associated with antidepressant effects (Trullas & Skolnick, 1990; Przegalinski et al. 1997).”
BackgroundKnable, M. B., Barci, B. M., Bartko, J. J., Webster, M. J., & Torrey, Ε. F. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001034 · Cited by 109 · cited 1×
“Post-mortem characterizations support the notion of dysfunctional glutamatergic signaling in MDD and BD (Knable et al. 2002; Sequeira et al. 2009; Deschwanden et al. 2011).”
BackgroundFrom the British Journal of Anaesthesia
Reilly, C. S., & Hunter, J. M. (2009) · British Journal of Anaesthesia · doi:10.1093/bja/aep308 · Cited by 77
Gröndal, G. W. (1993) · Evaluation Practice · doi:10.1177/109821409301400218 · Cited by 57
Meta-analytic procedures for social research
Gröndal, G. W. (1993) · Evaluation Practice · doi:10.1016/0886-1633(93)90018-k · Cited by 55
INDWELLING VENOUS CANNULA IN THE RAT
Dedrick, D. F., & BlEBUYCK, J. F. (1975) · British Journal of Anaesthesia · doi:10.1093/bja/47.2.162 · Cited by 42
Correction of table 1 in Darko et al. (1988)
Darko, D. F. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90217-5 · Cited by 1
Research works printed but not linked: 3
- Bastos, 2012, British Journal of Anaesthesia
- 2008, The Global Burden of Disease: 2004 Update
- 1992, The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines
Cited by
Turecki, G., Brent, D. A., Gunnell, D., O’Connor, R. C., Oquendo, M. A., Pirkis, J., & Stanley, B. H. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0121-0 · Cited by 1,074
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Neuroscience of apathy and anhedonia: a transdiagnostic approach
Husain, M., & Roiser, J. P. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0029-9 · Cited by 640
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Metadata
- Authors
- McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W.
- Affiliations
- University of British Columbia (CA)
- Douglas Mental Health University Institute (CA)
- University of Minnesota (US)
- Corresponding author
- McGirr, A.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2014-07-10
- Volume
- 45
- Issue
- 4
- Pages
- 693-704
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W2117269242
- Cited by
- 373
- References
- 57
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 19 · 2023: 30 · 2022: 22 · 2021: 41 · 2020: 53 · 2019: 36 · 2018: 32 · 2017: 32 · 2016: 33 · 2015: 43 · 2014: 9
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychological Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, major depressive disorder, bipolar depression, rapid-acting antidepressants, NMDA receptor antagonists, glutamatergic agents, clinical remission, clinical response, intranasal ketamine, intravenous ketamine, psychotomimetic effects
- MeSH terms
- Depressive Disorder, Major, Major Depressive Disorder, Humans, Ketamine, Randomized Controlled Trials as Topic, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.